NCT00998296View on ClinicalTrials.gov

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

July 31, 2014

Conditions
Neoplasms
Interventions
DRUG

BIBW 2992

EGFR inhibitor

DRUG

BIBF 1120

VEGF inhibitor

Trial Locations (1)

Unknown

1239.14.3301A Boehringer Ingelheim Investigational Site, Villejuif

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00998296 - Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | Biotech Hunter | Biotech Hunter